A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...
GlobalData on MSN

Gossamer Bio reports topline Phase III PROSERA outcomes for PAH

Of the 390 patients enrolled, 197 received seralutinib and 193 received placebo.

Precise Bio Announces Successful Transplantation of Additional Patients in Ongoing Clinical Study of 3D-Bio-Printed Corneal Implant

Continued clinical progress follows regulatory authorization to advance study First patient continues to show dramatic vision restoration GREENSBORO, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Precise ...
STAT

Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.

Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation

Study represents a significant advancement in Grove’s Bionic Biologics™ platform – CHICAGO--(BUSINESS WIRE)--February 24, 2026-- Grove Biopharma, ...

Gossamer Bio shares plummet as lung disease drug fails late-stage trial

By Sahil Pandey and Siddhi Mahatole Feb 23 (Reuters) - Gossamer Bio's experimental treatment failed to significantly improve ...
AgWeb

Study finds Pivot Bio PROVEN® 40 Increases Grower Revenue

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...